Photo detail

Nicole Harriott, director of chemistry of Neurocrine Biosciences, prepares a sample at a company lab as part of the drug discovery and development process. Neurocrine banked on the neuroscience, which has paid off. Photo courtesy of Neurocrine Bioscienes

Stories this photo appears in:

Neuroscience May Belong to the Nimble

MEDICINE: Big Players Bail, But Midsize Cos. Aim for Next Big Thing

Amid big pharma’s waning commitment to neurological disorders like Alzheimer’s, San Diego startups and midstage biotechs see opportunity.

Tease photo